Abstract 19P
Background
County-level hospitals, as the "gatekeepers" for rural cancer patients (pts) in the hierarchical diagnosis and treatment system (HDTS) in China, shoulder significant responsibilities in facilitating cancer treatment and patient referrals. Here, we report the referral data from the CHASE001 trial (NCT05544123).
Methods
CHASE001, a prospective, non-interventional multicenter study exploring real-world treatment and referral practices among pts in Chinese county-level hospitals with HER2+ or HR+/HER2- breast cancer (BC) is ongoing since Sep. 2022. The primary endpoint is to describe the treatment patterns. A key secondary endpoint is referral behavior. Descriptive statistics were utilized to analyze the referral data.
Results
At data cutoff (May 17, 2023), 1436 BC pts were included from 26 county-level hospitals in China. 1172 (81.62%) pts were initially diagnosed at county-level hospitals, among them, 81 (6.91%) pts were subsequently referred to higher-level hospitals. 58 out of 81 pts were referred out primarily to receive breast surgery (71.60%), and most of them were eventually referred back to county-level hospitals to receive adjuvant systemic treatment (94.83%, 55/58). Among 264 pts who were initially diagnosed at higher-level hospitals, a significant portion (84.09%) were referred to county-level hospitals to receive adjuvant systemic treatment. The majority (75.99%, 1092/1436) underwent the entire process of diagnosis and treatment within the county-level hospitals without requiring referral-out, however. Among 341 pts who received treatment at higher-level hospitals, 153 (44.87%) brought back their treatment plan to county-level hospitals, and the majority (90.20%, 138/153) adhered to that treatment plan. Interestingly, pts with higher education levels, and employee medical insurance were more inclined to seek treatment at higher-level hospitals, primarily to recieve breast surgery and neoadjuvant treatment.
Conclusions
Most of the patients admitted to county-level hospitals in China underwent the entire process of diagnosis and treatment within these hospitals, indicated that further efforts to provide high quality, guideline centric care should be concentrated at county-level hospitals.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract